These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20201829)

  • 1. Failure of bacille Calmette-Guérin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options.
    Yates DR; Rouprêt M
    BJU Int; 2010 Jul; 106(2):162-7. PubMed ID: 20201829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
    Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
    BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P; Turkeri L
    Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
    Sternberg IA; Dalbagni G; Chen LY; Donat SM; Bochner BH; Herr HW
    J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
    Yates DR; Brausi MA; Catto JW; Dalbagni G; Rouprêt M; Shariat SF; Sylvester RJ; Witjes JA; Zlotta AR; Palou-Redorta J
    Eur Urol; 2012 Dec; 62(6):1088-96. PubMed ID: 22959049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D; Brausi M; O'Donnell MA; Witjes JA
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial.
    Di Lorenzo G; Perdonà S; Damiano R; Faiella A; Cantiello F; Pignata S; Ascierto P; Simeone E; De Sio M; Autorino R
    Cancer; 2010 Apr; 116(8):1893-900. PubMed ID: 20162706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatments for BCG failure in non-muscle invasive bladder cancer (NMIBC).
    Álvarez-Maestro M; Guerrero-Ramos F; Rodríguez-Faba O; Domínguez-Escrig JL; Fernández-Gómez JM
    Actas Urol Esp (Engl Ed); 2021 Mar; 45(2):93-102. PubMed ID: 33012593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical Gemcitabine for Non-Muscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure: A Prospective Study.
    Mirzaee E; Novin K; Fadavi P; Soltani S; Kafash Nayeri R; Amanollahi A; Arefpour AM
    Asian Pac J Cancer Prev; 2024 Sep; 25(9):3173-3177. PubMed ID: 39342596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical gemcitabine for non-muscle invasive bladder cancer.
    Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
    Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage.
    Balasubramanian A; Gunjur A; Weickhardt A; Papa N; Bolton D; Lawrentschuk N; Perera M
    World J Urol; 2022 May; 40(5):1111-1124. PubMed ID: 35083522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage therapeutic strategies for bacillus Calmette-Guerin failure.
    Hassler MR; Shariat SF; Soria F
    Curr Opin Urol; 2019 May; 29(3):239-246. PubMed ID: 30762670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line intravesical therapy versus cystectomy for bacille Calmette-Guérin (BCG) failures.
    Joudi FN; O'Donnell MA
    Curr Opin Urol; 2004 Sep; 14(5):271-5. PubMed ID: 15300147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nonmuscle-invasive bladder cancer (NMIBC): when to perform cystectomy?].
    Lebret T
    Prog Urol; 2008 May; 18 Suppl 5():S111-4. PubMed ID: 18585632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidisciplinary consensus document on the current treatment of bacille Calmette-Guérin-unresponsive non-muscle invasive bladder tumor.
    Guerrero-Ramos F; Álvarez-Maestro M; Pinto Marín Á; Domínguez Escrig JL; Rodríguez Faba Ó
    Actas Urol Esp (Engl Ed); 2024 May; 48(4):262-272. PubMed ID: 38575068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bacillus of Calmette-Guérin immunotherapy: which protocol?].
    Saint F
    Prog Urol; 2008 May; 18 Suppl 5():S99-104. PubMed ID: 18585635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel treatments in BCG failure. Where do we stand today?
    Fragkoulis C; Glykas I; Bamias A; Stathouros G; Papadopoulos G; Ntoumas K
    Arch Esp Urol; 2021 Sep; 74(7):681-691. PubMed ID: 34472437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure.
    Hurle R; Contieri R; Casale P; Morenghi E; Saita A; Buffi N; Lughezzani G; Colombo P; Frego N; Fasulo V; Paciotti M; Guazzoni G; Lazzeri M
    Urol Oncol; 2021 Mar; 39(3):195.e7-195.e13. PubMed ID: 33268275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Failure of Bacillus Calmette-Guérin therapy in non-muscle-invasive bladder cancer: Definition and treatment options.
    Gual Frau J; Palou J; Rodríguez O; Parada R; Breda A; Villavicencio H
    Arch Esp Urol; 2016 Sep; 69(7):423-33. PubMed ID: 27617552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.